ICA-1S has previously shown promising efficacy in neuroblastoma, renal cell carcinoma, and some other cancers by inhibiting PKC-ι and also showed lower toxicity in a preclinical trial [22,23,24]. The gene discussed is PRKCI; the disease is cancer.